BEUDAMED
    FDA Enforcement Class II Terminated

    G3 Opticage Expandable Interbody Fusion Device, Model No. 9180-00, 9180-01, 9180-06, 9180-07, 9180-17, 9101-00, 9101-06 The Opticage Expandable Interbody Fusion Device is a posterior lumbar intervertebral body fusion device and is indicated for use with autogenous bone graft in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2-S1. These DDD patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved level(s). The Opticage Interbody Fusion Device can be implanted via posterior, transforaminal or lateral approach. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. Candidates for surgery should be skeletally mature and have had six months of conservative treatment. These patients may have had primary or secondary surgery, but no previous fusion at the involved levels. The device is not intended to be used as a stand-alone device. It must be used with supplemental internal spinal fixation systems that have been cleared for use in the lumbar spine (i.e. facet screw fixation systems, facet compression devices and posterior pedicle screw and rod systems).

    Recall: Z-0941-2017 · Reported January 11, 2017

    Enforcement

    Recall Number
    Z-0941-2017
    Event ID
    75882
    Classification
    Class II
    Status
    Terminated
    Product Type
    Devices
    Firm
    Interventional Spine Inc
    Voluntary / Mandated
    Voluntary: Firm initiated
    Initial Notification
    Letter
    Report Date
    January 11, 2017
    Initiation Date
    November 22, 2016
    Classification Date
    January 3, 2017
    Termination Date
    February 7, 2017
    Address
    13700 Alton Pkwy Ste 160, N/A, Irvine, CA, 92618-1618, United States

    Description

    G3 Opticage Expandable Interbody Fusion Device, Model No. 9180-00, 9180-01, 9180-06, 9180-07, 9180-17, 9101-00, 9101-06 The Opticage Expandable Interbody Fusion Device is a posterior lumbar intervertebral body fusion device and is indicated for use with autogenous bone graft in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2-S1. These DDD patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved level(s). The Opticage Interbody Fusion Device can be implanted via posterior, transforaminal or lateral approach. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. Candidates for surgery should be skeletally mature and have had six months of conservative treatment. These patients may have had primary or secondary surgery, but no previous fusion at the involved levels. The device is not intended to be used as a stand-alone device. It must be used with supplemental internal spinal fixation systems that have been cleared for use in the lumbar spine (i.e. facet screw fixation systems, facet compression devices and posterior pedicle screw and rod systems).

    Reason

    During implantation, the proximal end of the device could separate if the angle between the device and insertion instrument is too steep. This separation will prevent the device from expanding.

    Code Info

    Lot no. 011416-D 021216-A 021216-B 032015-B 032015-C 033116-B 040915-B 040915-E 041416-A 060116-A 060116-B 060116-C 061616-B 061915-A 061915-B 070714-D 071116-A 071116-B 071116-C 071516-A 071516-B 071916-A 081016-A 081016-B 081016-C 083116-B 083116-B 091516-A 112515-A 033116-C 030716-A 081016-E 090216-C 090216-C 090216-D 030716-B 011416-E 021216-C 081016-F 081016-G 090216-A 090216-A 090216-B 081016-H 083116-C 083116-C 083116-D

    Distribution

    Nationwide Distribution to NY, NC, SC, PA, TX, OH, GA, NJ, DE, AZ, DC, CA, and VA.

    Quantity

    239 units